ANTERIS TECHNOLOGIES GLOBAL CORP. COMMON STOCK
NASDAQ: AVR (Anteris Technologies Global Cor)
Last update: 4 hours ago5.68
0.17 (3.09%)
| Previous Close | 5.51 |
| Open | 5.58 |
| Volume | 497,288 |
| Avg. Volume (3M) | 1,352,040 |
| Market Cap | 552,278,080 |
| Price / Sales | 106.32 |
| Price / Book | 165.91 |
| 52 Weeks Range | |
| Earnings Date | 11 May 2026 |
| Operating Margin (TTM) | -3,917.27% |
| Diluted EPS (TTM) | -3.47 |
| Quarterly Revenue Growth (YOY) | -27.40% |
| Total Debt/Equity (MRQ) | 4.68% |
| Current Ratio (MRQ) | 3.67 |
| Operating Cash Flow (TTM) | -67.20 M |
| Levered Free Cash Flow (TTM) | -48.03 M |
| Return on Assets (TTM) | -135.31% |
| Return on Equity (TTM) | -263.65% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Anteris Technologies Global Cor | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -1.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -2.0 |
| Average | -0.38 |
|
Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 0.21% |
| % Held by Institutions | 64.12% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| L1 Capital Pty Ltd | 31 Dec 2025 | 2,812,000 |
| Sio Capital Management, Llc | 31 Dec 2025 | 1,874,641 |
| Ensign Peak Advisors, Inc | 31 Dec 2025 | 1,400,555 |
| Rhenman & Partners Asset Management Ab | 31 Dec 2025 | 1,238,625 |
| Affinity Asset Advisors, Llc | 31 Dec 2025 | 486,684 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 16.00 (Wells Fargo, 181.69%) | Buy |
| Median | 15.50 (172.89%) | |
| Low | 15.00 (Cantor Fitzgerald, 164.09%) | Buy |
| Average | 15.50 (172.89%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 6.64 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 12 Mar 2026 | 15.00 (164.08%) | Buy | 6.58 |
| Wells Fargo | 11 Mar 2026 | 16.00 (181.69%) | Buy | 6.69 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 22 Jan 2026 | Announcement | Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises |
| 22 Jan 2026 | Announcement | Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock |
| 20 Jan 2026 | Announcement | Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering |
| 20 Jan 2026 | Announcement | Anteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from Medtronic |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |